ANTCF (Aion Therapeutic) Book Value per Share: $-0.01 (As of Jan. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aion Therapeutic Book Value per Share?

Aion Therapeutic ANTCF Book Value per Share is $-0.01 as of Jan. 2025.

Aion Therapeutic's book value per share for the quarter that ended in Jan. 2025 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Aion Therapeutic's current price is $0.002. Its book value per share for the quarter that ended in Jan. 2025 was $-0.01. Hence, today's PB Ratio of Aion Therapeutic is .

Aion Therapeutic  (OTCPK:ANTCF) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Aion Therapeutic Book Value per Share Related Terms

Aion Therapeutic Book Value per Share Historical Data

* Premium members only.

The historical data trend for Aion Therapeutic's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aion Therapeutic Book Value per Share Chart

Aion Therapeutic Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Book Value per Share
Get a 7-Day Free Trial 0.04 0.00 -0.01 -0.01 -0.01

Aion Therapeutic Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.01 -0.01 -0.01 -0.01

ANTCF vs CBDY, GRPS, PLSH: Book Value per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aion Therapeutic PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's PB Ratio distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's PB Ratio falls into.


Aion Therapeutic Book Value per Share Calculation

Aion Therapeutic's Book Value Per Share for the fiscal year that ended in Apr. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-2.82-0.00)/411.55
=-0.01

Aion Therapeutic's Book Value Per Share for the quarter that ended in Jan. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-3.23-0.00)/497.15
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $-0.01 mean?
Aion Therapeutic (ANTCF) has a Book Value per Share of $-0.01 as of Jan. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Aion Therapeutic and its competitors.
Is Aion Therapeutic's Book Value per Share too high?
Aion Therapeutic's current Book Value per Share is $-0.01.
How does Aion Therapeutic's Book Value per Share compare to CBDY and GRPS?
Aion Therapeutic's Book Value per Share of $-0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Aion Therapeutic and its competitors. Aion Therapeutic's current Book Value per Share is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aion Therapeutic stock overvalued right now?
Aion Therapeutic (ANTCF) has a current Book Value per Share of $-0.01. The current Book Value per Share is $-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Aion Therapeutic (ANTCF), the current Book Value per Share is $-0.01 as of Jan. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aion Therapeutic Business Description

Address 700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery. During the year ended the Company had one operating segment, being health and wellness, dedicated to delivering state-of-the-art water filtration solutions. Geographically company earns revenue from USA.